| Cardiovascular Diseases
Crestor vs Glyxambi
Side-by-side clinical, coverage, and cost comparison for cardiovascular diseases.Deep comparison between: Crestor vs Glyxambi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGlyxambi has a higher rate of injection site reactions vs Crestor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Glyxambi but not Crestor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Crestor
Glyxambi
At A Glance
Oral
Once daily
HMG-CoA reductase inhibitor
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
Indications
- Cardiovascular Diseases
- Hyperlipidemia
- Atherosclerosis
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Cardiovascular Diseases, Hyperlipidemia, Atherosclerosis, Hypertriglyceridemia 5-40 mg orally once daily in adults.
Hypercholesterolemia, Familial HeFH: 5-10 mg once daily (ages 8 to <10 years) or 5-20 mg once daily (ages 10+); HoFH: 20 mg once daily (ages 7+); adults: 5-40 mg once daily.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or any excipient in CRESTOR
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
Adverse Reactions
Most common (>=2%) headache, nausea, myalgia, asthenia, constipation, arthralgia, dizziness, increased CPK, abdominal pain, diabetes mellitus
Serious myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria, hematuria, increases in HbA1c and fasting serum glucose
Postmarketing thrombocytopenia, hepatitis, jaundice, hepatic failure, peripheral neuropathy, cognitive impairment, myasthenia gravis, depression, sleep disorders, gynecomastia, interstitial lung disease, DRESS, lichenoid drug eruption
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Pharmacology
CRESTOR (rosuvastatin) is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor); inhibition accelerates hepatic LDL-receptor expression, reducing plasma LDL-C, total cholesterol, and VLDL levels.
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Crestor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
UnitedHealthcare
Crestor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Humana
Crestor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Crestor.
No savings programs available for Glyxambi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CrestorView full Crestor profile
GlyxambiView full Glyxambi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.